Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential prednisolone and budesonide taper study in COPD using exhaled nitric oxide
ACTRN12614000752662Phase 4Withdrawn
- Sponsor
- Dr Jack Dummer
- Start
- Aug 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of prednisolone and budesonide in chronic obstructive pulmonary disease (COPD), sponsored by Dr Jack Dummer. Primary endpoint: Change in exhaled nitric oxide with steroid reduction. Planned start Aug 2014; status: withdrawn.
02
Drugs
prednisolonebudesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12614000752662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000752662.